PULMONX CORP

Insider buying spree at PulmonX: executives pile on 40‑k shares amid a 54% YTD decline, signaling confidence in a potential rebound below the $1.49 price.

Insider sales at Pulmonx reveal routine tax‑settlement trades, not panic—analyzing CEO, CFO, and COO moves, Zephyr valve milestones, and what investors should watch next.

Pulmonx insider sales reveal a “sell‑to‑cover” pattern and a new RSU grant, hinting at long‑term confidence amid a steep 80% YTD decline. Read why this matters for investors.